You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204760

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 204760 describes MOVANTIK, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MOVANTIK profile page.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.
Summary for 204760
Applicant:Astrazeneca Pharms
Ingredient:naloxegol oxalate
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 204760
Generic Entry Date for 204760*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204760
Mechanism of ActionOpioid Antagonists
Suppliers and Packaging for NDA: 204760
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOVANTIK naloxegol oxalate TABLET;ORAL 204760 NDA AstraZeneca Pharmaceuticals LP 0310-1969 0310-1969-30 30 TABLET, FILM COATED in 1 BOTTLE (0310-1969-30)
MOVANTIK naloxegol oxalate TABLET;ORAL 204760 NDA AstraZeneca Pharmaceuticals LP 0310-1969 0310-1969-39 10 BLISTER PACK in 1 CARTON (0310-1969-39) > 10 TABLET, FILM COATED in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 204760
Tradename Dosage Ingredient NDA Submissiondate
MOVANTIK TABLET;ORAL naloxegol oxalate 204760 2018-09-17

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 12.5MG BASE
Approval Date:Sep 16, 2014TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 29, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Oct 18, 2022Product Flag?YSubstance Flag?YDelist Request?
Patent:  Start TrialPatent Expiration:Dec 19, 2027Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.